Phase III
As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.
The trial was assessing if multiple myeloma drug Empliciti could move forward as a front-line treatment for the disease.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
The company said its combination treatment of Imfinzi (durvalumab) plus tremelimumab, an anti-CTLA4 antibody and Imfinzi on its own, did not improve overall survival in patients with this advanced form of bladder cancer.
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
“This dosing is a truly historic event—for science, for medicine, and most importantly for people living with this eye disease,” said Cynthia Collins, president and chief executive officer of Editas.
Life sciences companies from across the globe provide updates on their businesses and pipelines.
Karyopharm Therapeutics posted positive Phase III results in multiple myeloma and announced it is planning a regulatory submission in the second quarter of this year for its combination of Xpovio, Velcade and Dexamethasone.
EyePoint Pharmaceuticals announced positive topline 36-month follow-up data from the second Phase III trial of Yutiq (fluocinolone acetonide intravitreal implant) for treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
The month of February ended with a flurry of clinical trial announcements. Here’s a look.
PRESS RELEASES